Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials ≥1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis

Author:

Matchaba Patrice,Gitton Xavier,Krammer Gerhard,Ehrsam Elena,Sloan Victor Schorr,Olson Melvin,Mellein Bernhard,Hoexter Godehard,Orloff John,Garaud Jean-Jacques

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference54 articles.

1. Merck & Company, Inc. Merck announces voluntary worldwide withdrawal of VIOXX®. Available at: http://www.vioxx.com/vioxx/documents/english/vioxx_press_release.pdf. Accessed May 12, 2005.

2. National Institutes of Health. NIH halts use of COX-2 inhibitor in large cancer prevention trial. Available at: http://www.nih.gov/news/pr/dec2004/od-17.htm. Accessed May 12, 2005.

3. Parecoxib, valdecoxib, and cardiovascular risk;Furberg;Circulation,2005

4. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis;Juni;Lancet,2004

5. European Medicines Agency. European Medicines Agency announces regulatory action on COX-2 inhibitors. Available at: http://www.emea.eu.int/htms/hotpress/d6275705.htm. Accessed May 12, 2005.

Cited by 51 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3